INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
๐Ÿ‡ฎ๐Ÿ‡ณ
Home/Topics/Companies & Institutions/Merck
Back to Newsroom
๐ŸขOrganization Dossier

Merck

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

2 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Global Health & Biotech 26 Oct 2026, 08:00 PM IST

Landmark Melanoma Vaccine Trial Cuts Recurrence or Death Risk by 42%, Raising Stakes for Cancer Biotech

A first-of-its-kind personalized cancer vaccine has reduced the risk of melanoma recurrence or death by 42% in a landmark trial, according to reports from the European Society for Medical Oncology meeting. The result strengthens the case for individualized immunotherapy and could reshape investor expectations for Moderna, Merck, and the broader oncology biotech sector.

By RDU Global Wire4 min read
Global Health & Biotech15 Oct 2026, 09:30 PM IST

Merck CEO Says Personalized Cancer Vaccine Could Be Made Faster as Pipeline Advances

Merck Chief Executive Robert Davis told CNBC he expects the companyโ€™s experimental personalized cancer vaccine to become faster to manufacture over time, signaling a potential shift from early-stage scientific promise toward more scalable production. The comments add fresh attention to a closely watched oncology program that investors view as a possible long-term growth driver for Merck and a broader test case for the commercial viability of personalized cancer immunotherapy.

5 min readRead โ†’

๐Ÿข About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Merck: